Biological behavior of keratoacanthoma and squamous cell carcinoma: Telomerase activity and COX-2 as potential markers

Modern Pathology

Volumn 17, Issue 4, 2004, Pages 468-475

  Putti, Thomas C ^a,b   Teh, Ming ^a   Lee, Yoke S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Cyclooxygenase 2; Immunohistochemistry; Keratoacanthoma; p53; Squamous cell carcinoma; Telomerase

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; PROTEIN P53; TELOMERASE; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; KERATOACANTHOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ADOLESCENT; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; ISOENZYMES; KERATOACANTHOMA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RETROSPECTIVE STUDIES; RNA, NEOPLASM; SKIN NEOPLASMS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4644342420     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800063     Document Type: Article

References (34)

1. Elders J. Lever's Histopathology of Skin, 8th ed. Lippincott-Raven: Philadelphia, NY, 1997.
2. Ackerman AB, Mendonca AMN, Guo Y. Keratoacanthoma vs squamous cell carcinoma. In: Differential Diagnosis in Dermatopathology I, 2nd ed. Lea & Febiger: Philadelphia/London, 1992.
3. LeB oit PE. Is keratoacanthoma a variant of squamous cell carcinoma? New insights into an old controversy... soon? Am J Dermatopathol 1995;4:319-320.
4. Rook A, Whimster I. Keratoacanthoma-A thirty-year retrospect. Br J Dermatol 1979;100:41-47.
5. Cribier B, Asch P-H, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999;199:208-212.
6. Pilch H, Weiss J, Heubner C, et al. Differential diagnosis of keratoacanthomas and squamous cell carcinomas: diagnostic value of DNA image cytometry and p53 expression. J Cutan Pathol 1994;21:507-513.
7. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994;130:181-186.
8. Stephenson TJ, Royds J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992;127:566-570.
9. Tsuji T. Keratoacanthoma and squamous cell carcinoma: study of PCNA and Le(Y) expression. J Cutan Pathol 1997;24:409-415.
10. Krunic ALJ, Garrod DR, Smith NP, et al. Differential expression of desmosomal glycoproteins in keratoacanthoma and squamous cell carcinoma of the skin: An immunohistochemical aid to diagnosis. Acta Derm Venereol 1996;76:394-398.
11. Krunic AL, Garrod DR, Madani S, et al. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype; actinic keratosis, keratoacanthoma and squamous cell carcinoma of skin. Br J Cancer 1998;77:1275-1279.
12. Tran TA, Ross JS, Boehm JR, et al. Comparison of mitotic cyclins and cyclin dependent kinase expression in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1999;26:391-397.
13. Tran TA, Ross JS, Sheehan CE, et al. Comparison of Oncostatin M expression in keratoacanthoma and squamous cell carcinoma. Mod Pathol 2000;13:427-432.
14. Jensen P, Clausen OP, Bryne M. Differences in sialyl-Tn antigen expression between keratoacanthomas and cutaneous squamous cell carcinomas. J Cutan Pathol 1999;26:183-189.
15. Mukunyadzi P, Sanderson RD, Fan CY, et al. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol 2002;15:45-49.
16. Takedo H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001;158:1633-1637.
17. Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002;119:1367-1372.
18. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
19. Rhyu MS. Telomeres, telomerase and immortality. J Nat Cancer Inst 1995;87:884-894.
20. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
21. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
22. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast Rev 2000;19:19-25.
23. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
24. Harris AL. Mutant p53-the commonest genetic abnormality in human cancer? J Pathol 1990;162:5-6.
25. Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol 1994;102:440-444.
26. Perez MI, Robins P, Biria S, et al. P53 oncoprotein expression and gene mutations in some keratoacanthomas. Arch Dermatol 1997;Feb:133:189-193.
27. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993;4:332-342.
28. Herbsleb M, Knudsen UB, Orntoft TF, et al. Telomerase activity, MIB-1, PCNA, HPV-16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 2001;109:607-617.
29. Taylor RS, Ramirez RD, Ogoshi M, et al. Detection of telomerase activity in malignant and non-malignant skin conditions. J Invest Dermatol 1996;106:759-765.
30. Wu A, Ichihashi M, Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal and skin tumors. Cancer 1999;86:2038-2044.
31. Rudolph P, Schubert C, Tamm S, et al. Telomerase activity in melanocytic lesions; a potential marker of tumor Biology. Am J Pathol 2000;156:1425-1432.
32. Yoo K, Robinson RA. Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas. Arch Pathol Lab Med 2000;124:393-397.
33. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
34. Thumher D, Bakroeva M, Formanek M, et al. Non-steroidal anti-inflammatory drugs inhibit telomerase activity in head and neck squamous carcinoma cell lines. Head Neck 2001;23:1049-1055.